Diagnostic accuracy of neuroblastoma patient imaging with [18F]-mFBG PET-CT compared to [123I]mIBG scanning

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON28070

Enrollment

Registered

2019-11-12

Start date

2020-07-12

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuroblastoma

Interventions

[18F]mFBG PET CT

Eligibility

Inclusion criteria

Inclusion criteria: patients with a (clinical suspicion of) neuroblastoma who are referred for [123I] mIBG imaging, 0-18 years of age

Exclusion criteria

Exclusion criteria: pregnancy of the patient and above 18 years old

Design outcomes

Primary

Measure	Time frame
The primary study endpoints are the number of lesions and sites of disease detected with 18F-mFBG PET-CT compared to the current imaging standard of care, 123I-mIBG scan using the SIOPEN imaging scoring method for skeletal lesions and the total number of detected soft tissue lesions	—

Secondary

Measure	Time frame
o Determine optimum imaging time of 18F-mFBG PET CT(60 min vs 120-150 min post injection) o Determine the estimation of radiation absorbed dose of 18F-mFBG o Adverse events of 18F-mFBG injection and PET CT s	—

Contacts

Public ContactYvonne Ruchti

Prinses Maxima Centrum

y.j.ruchti@prinsesmaximacentrum.nl0889727272

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)